Setting the Course for Comprehensive Care Navigation in Oncology Evolent experts describe the key pieces of a scalable, comprehensive care navigation program in an article in Evidence-Based Oncology. Read Article
From every angle: Dr. Von Nguyen brings rare background to quest for high-value specialty care Chief Medical Officer Von Nguyen brings a background in value-based payment models, artificial intelligence and health plan operations to Evolent. Read Article
Scientific investment in precision oncology Dr. Sadie Dobrozsi joins the Oncology Overdrive podcast to discuss issues in genomics testing, from its role in treatment planning to ethical concerns. Read Article
Advances in ovarian cancer: Using genomics and optimizing maintenance therapy Writing in Evidence-Based Oncology, oncology pharmacist Amy VanGalder explores how genomic profiling is enabling clinicians to tailor therapies with greater precision. Read Article
Q&A: The importance of patient selection for immunotherapy drugs Dr. Andrew Hertler speaks with Urban Health Today about the need to identify patients most likely to benefit from PD-L1 inhibitors. Read Article
Too many ovarian cancer patients are missing out on life-changing genetic testing Dr. Sadie Dobrozsi talks with Patient Power about overcoming the barriers to testing. Read Article
Q&A: Cardiotoxicity among cancer patients Oncology pharmacist Terra Wonsettler speaks with Urban Health Today about a serious side effect of certain cancer treatments – damage to the heart. Read Article
Evolent program achieves 20% reduction in use of low-value oncology regimens Program aims to achieve the best possible treatment outcomes — longer lives with fewer side-effects — without excess financial strain. Read Press Release
Clinical trials must represent those who will receive therapy Real-world patients often experience worse outcomes than those seen in clinical trials. Lack of representation may be one reason, writes Dr. Andrew Hertler. Read Article
The case for shorter radiation therapy courses The evidence supports hypofractionation in many cancer treatment scenarios, but there are still many missed opportunities. Read Article
